The Importance of an NCI SPORE Grant

Jeffrey S. Weber, MD, PhD
Published Online: October 31, 2013
Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a Specialized Programs of Research Excellence (SPORE) grant.

Clinical Pearls

  • A Specialized Programs of Research Excellence (SPORE) grant is given out by the NCI
  • SPORE grants bring together investigators from all different disciplines focused on one histology
  • As a part of the SPORE grant given to Moffitt Cancer Center, each project has preclinical laboratory pieces leading to a clinical trial
  • Two out of three SPORE projects at Moffitt currently have clinical trials ongoing


Related Articles
A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis.
The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved progression-free survival (PFS) compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.
The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.
Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma
JTT Articles
The Transformation of Treatment in CLL: A Q & A With Dr. William G. Wierda
Searching for Positives in Triple-Negative Breast Cancer
Immunotherapies in CRPC: Progress Evident but Not Without Challenges
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.